Order a Diagnostic PSA Test
In a patient with a history of prostate cancer, you should order a diagnostic PSA test, not a screening PSA, as this is surveillance for biochemical recurrence following definitive treatment.
Rationale for Diagnostic vs. Screening PSA
The distinction is critical for several reasons:
- Screening PSA is used for early detection in asymptomatic men without known prostate cancer
- Diagnostic PSA is appropriate for monitoring disease status, detecting recurrence, or evaluating treatment response in patients with established prostate cancer history
In your patient with prior prostate cancer, the PSA serves a diagnostic/surveillance function to detect biochemical recurrence (BCR), not to screen for new disease 1.
Post-Treatment Surveillance Guidelines
The frequency and interpretation of PSA testing depends on the primary treatment received:
After Radical Prostatectomy
- PSA should be undetectable (<0.1 ng/mL) within 6-8 weeks after surgery 1
- Measure PSA every 6-12 months for the first 5 years, then annually 2
- For high-risk patients, PSA testing every 3 months may be required 2
- Biochemical recurrence is defined as PSA ≥0.2 ng/mL confirmed on two successive measurements 1, 3, 4
After Radiation Therapy
- PSA falls more gradually and may not reach undetectable levels 4
- Monitor PSA every 6 months for 5 years, then annually 2
- BCR after radiation is defined by the Phoenix criteria: PSA rise of ≥2.0 ng/mL above nadir 4
- "PSA bounces" can occur and don't necessarily indicate recurrence 4
Clinical Implications
Common Pitfall: Ordering a "screening" PSA in a patient with cancer history may result in:
- Incorrect billing/coding
- Potential insurance denial
- Missed opportunity for appropriate surveillance intervals
- Failure to trigger appropriate workup thresholds for recurrence
The diagnostic PSA allows proper:
- Risk stratification based on PSA kinetics (doubling time, velocity) 1, 4
- Timing of imaging studies when BCR is detected 1
- Treatment decisions for salvage therapy 2, 5
PSA Kinetics Matter
When BCR is detected, PSA kinetics help determine if recurrence is local vs. metastatic 1:
- Local recurrence more likely: Late BCR (>24 months post-treatment), PSA doubling time >6 months, low PSA velocity
- Metastatic disease more likely: Early BCR (<24 months), PSA doubling time <6 months, rapid PSA velocity
This distinction guides whether to pursue local salvage therapy vs. systemic treatment 1, 5.
Imaging Considerations
Do not routinely order imaging at time of PSA testing unless BCR is confirmed 1: